EP744 Assessing the impact of clinicopathologic features and recurrence patterns of Uterine Carcinosarcomas: an institutional analysis. (1st November 2019)

• Record Type: Journal Article
• Authors: Papapanagiotou, IK; Thomakos, N; Ntzeros, K; Vlachos, D-E; Haidopoulos, D; Sotiropoulou, M; Liontos, M; Bamias, A; Rodolakis, A
• Is Part Of: International journal of gynecological cancer. Volume 29(2019)Supplement 4
• Page Start: A417
• Page End: A417
• Publication Date: 2019-11-01
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2019-ESGO.796
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: Uterine Carcinosarcomas (UCs) are composed of both malignant epithelial and mesenchymal components, account for <5% of all gynecological neoplasms and have a highly aggressive clinical course. The aim of this retrospective study was to evaluate the recurrence patterns as well as the clinical and histopathological characteristics of UCs. Methodology: We retrospectively reviewed the clinical and pathology data from 46 patients who underwent surgery between 2012 and 2018 and obtained a diagnosis of UCs. Data analysis included histologic subtype, grade, presence of homologous/heterologous elements, depth of myometrial invasion (MI), disease - free interval (DFI), site of recurrent disease, and overall survival (OS). Data was analyzed using Cox-regression and Kaplan - Meier survival analyses. Results: The median age of our patient sample was 69.9 (range 35–91 years), and median tumor size was 6.4 cm. MI >50% was observed in 68.7%, LVI in 45.6%, and lymph node (LN) metastasis in 19.5%. 60.8% of the patients were diagnosed with stage I disease, 10.8% with stage II, and 28.2% with stage III disease. Serous carcinoma was the predominant carcinomatous component (56.5%), while heterologous elements (43.4%), particularly rhabdomyoblastic differentiation (RMB) (85%) was the most common sarcomatous component. 28% and 65% of patients received adjuvant radiotherapy or chemotherapy, respectively. Median DFI and OS were 10 and 16 months respectively. LN metastasis, tumor size >5 cm, MI >50%, LVI, advanced stage and positive cytology correlated with shorter DFI and worse 3 year OS (p<0.5 respectively). Recurrence developed outside the abdomen in 56.5%. Patients with tumors with sarcomatous histology upon recurrence and predominant sarcomatous component in primary tumor (≥50%) had shorter DFI (p< 0.5%). Conclusion: UCs represent a distinct subtype of uterine malignancy, where, according to our data, LN metastasis, tumor size, MI, stage and sarcomatous (RMB in particular) component have a significant prognostic role. Disclosure: Nothing to disclose.